Chronic obstructive pulmonary disease overview: Epidemiology, risk factors, and clinical presentation

Proceedings of the American Thoracic Society

Volumn 8, Issue 4, 2011, Pages 363-367

  Soriano, Joan B ^a   Rodríguez Roisin, Roberto ^b  

^a Recinte Hospital Joan March   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Epidemiology; Prevalence; Smoking; Trends

Indexed keywords

BIOLOGICAL MARKER;

ASTHMA; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE EXACERBATION; FORCED EXPIRATORY VOLUME; HUMAN; LUNG EMPHYSEMA; MORBIDITY; MORTALITY; PHENOTYPE; PREVALENCE; PROGNOSIS; RADIODIAGNOSIS; RESPIRATORY TRACT DISEASE; RHINITIS; RISK FACTOR; SCREENING; SLEEP DISORDERED BREATHING; SPIROMETRY; SURVIVAL;

HUMANS; PREVALENCE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; WORLD HEALTH;

EID: 80051706999     PISSN: 15463222     EISSN: 19435665     Source Type: Journal    
DOI: 10.1513/pats.201102-017RM     Document Type: Conference Paper

References (73)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997;349:1498-1504. (Pubitemid 27216360)
2. European Respiratory Society. European lung white book. Huddersfield: European Respiratory Society Journals Ltd.; 2003.
3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, et al.; Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555. (Pubitemid 47403272)
4. Bousquet J, Khaltaev N. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach [updated 2007; accessed June 30, 2011]. Available from: http://www.who.int/ gard/publications/ GARD%20Book%202007.pdf
5. Stockley RA, Mannino D, Barnes PJ. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6: 524-526.
6. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773. (Pubitemid 47321908)
7. Chapman KR, Mannino DM, Soriano JB, Vermeire PA, Buist AS, Thun MJ, Connell C, Jemal A, Lee TA, Miravitlles M, et al. Epidemiology and costs of chronic obstructive pulmonary disease. Eur Respir J 2006; 27:188-207. (Pubitemid 43092683)
8. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946. (Pubitemid 38807371)
9. Bellamy D. Bouchard J, Henrichsen S, Johansson G, Langhammer A, Reid J, van Weel C, Buist S. International Primary Care Respiratory Group (IPCRG) guidelines: management of chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2006;15:48-57. (Pubitemid 43155766)
10. Peces-Barba G, Barberà JA, Agust´ A, Casanova C, Casas A, Izquierdo JL, Jardim J, López Varela V, Monso E, Montemayor T, et al. Diagnosis and management of chronic obstructive pulmonary disease: joint guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic Society (ALAT) [in Spanish]. Arch Bronconeumol 2008;44:271-281.
11. O'Reilly J, Jones MM, Parnham J, Lovibond K, Rudolf M; Guideline Development Group. Management of stable chronic obstructive pulmonary disease in primary and secondary care: summary of updated NICE guidance. BMJ 2010;340:c3134.
12. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, Schmid V, Buist S. The Global Burden of COPD: future COPD projections. Eur Respir J 2006;27:397-412.
13. Murray CJ, Lopez AD, Black R, Mathers CD, Shibuya K, Ezzati M, Salomon JA, Michaud CM, Walker N, Vos T. Global burden of disease 2005: call for collaborators. Lancet 2007;370:109-110. (Pubitemid 47042879)
14. Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J 2006;28:781-785. (Pubitemid 46331999)
15. Mathers CD, Roncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:2011-2030. (Pubitemid 44875937)
16. International COPD Coalition. Quick facts about COPD [updated 2011; accessed June 30, 2011]. Available from: http://www.internationalcopd. org/materials/patients/learn/facts.aspx.
17. Bousquet J, Kiley J, Bateman ED, Viegi G, Khaltaev N, Cruz AA. Prioritized research agenda for prevention and control of chronic respiratory diseases. Eur Respir J 2010;36:995-1001.
18. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. Lancet 2009 29;374:721-732.
19. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28:523-532. (Pubitemid 44794666)
20. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Hallal PC, Victora CG; PLATINO Team. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005;366:1875-1881. (Pubitemid 41690116)
21. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, et al.; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370:741-750. (Pubitemid 47321907)
22. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009;374:1196-1208
23. Shafey O, Erisksen M, Ross H, MacKay J. The tobacco atlas 2009, 3rd ed. Atlanta: American Cancer Society and the World Lung Foundation; 2009.
24. Soriano JB, Ancochea J, Miravitlles M, Garcïa-Río F, Duran-Tauleria E, Muñoz L, Jiménez-Ruiz CA, Masa JF, Viejo JL, Villasante C, et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997-2007. Eur Respir J 2010;36:758-765.
25. Vasankari TM, Impivaara O, Heliövaara M, Heistaro S, Liippo K, Puukka P, Saarelainen S, Kanervisto M, Jousilahti P. No increase in the prevalence of COPD in two decades. Eur Respir J 2010;36:766-773.
26. Celli BR. The light at the end of the tunnel: is COPD prevalence changing? Eur Respir J 2010;36:718-719.
27. Cerveri I, De Marco R. What makes large epidemiological studies comparable? Eur Respir J 2010;36:720-721.
28. Soriano JB, Miravitlles M, Borderías L, Duran-Tauleria E, García Río F, Martínez J, Montemayor T, Muñoz L, Piñeiro L, Sánchez G, et al. Geographical variations in the prevalence of COPD in Spain: relationship to smoking, death rates and other determining factors [in Spanish]. Arch Bronconeumol 2010;46:522-530.
29. Lopez AD, Mathers CD. Measuring the global burden of disease and epidemiological transitions: 2002-2030. Ann Trop Med Parasitol 2006; 100:481-499. (Pubitemid 47050869)
30. Celli BR, Halbert RJ. Point: should we abandon FEV1/FVC, 0.70 to detect airway obstruction? No. Chest 2010;138:1037-1040.
31. Enright P, Brusasco V. Counterpoint: should we abandon FEV1/FVC, 0.70 to detect airway obstruction? Yes. Chest 2010;138:1040-1042.
32. Quanjer PH, Enright PL, Stocks J, Ruppel G, Swanney MP, Crapo RO, Pedersen OF, Falaschetti E, Schouten JP, Jensen RL, et al. Open letter to the members of the GOLD committee [in French]. Rev Mal Respir 2010;27:1003-1007.
33. Quanjer PH, Enright PL, Miller MR, Stocks J, Ruppel G, Swanney MP, Crapo RO, Pedersen OF, Falaschetti E, Schouten JP, et al. Open letter: the need to change the method for defining mild airway obstruction. Prim Care Respir J 2010;19:288-291.
34. García-Rio F, Soriano JB, Miravitlles M, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, Ancochea J. Subjects "over-diagnosed" as COPD by the 0.7 fixed ratio have a poor health-related quality of life. Chest (In press)
35. Chobanian AV. Shattuck Lecture: the hypertension paradox-more uncontrolled disease despite improved therapy. N Engl J Med 2009; 361:878-887.
36. Rose G. Sick individuals and sick populations. Int J Epidemiol 1985;14: 32-38. (Pubitemid 15109489)
37. Blanc PD, Menezes AM, Plana E, Mannino DM, Hallal PC, Toren K, Eisner MD, Zock JP. Occupational exposures and COPD: an ecological analysis of international data. Eur Respir J 2009;33:298-304.
38. Ezzati M, Hoorn SV, Rodgers A, Lopez AD, Mathers CD, Murray CJ; Comparative Risk Assessment Collaborating Group. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003;362:271-280. (Pubitemid 36936837)
39. 1-Antitrypsin deficiency. Lancet 2005;365: 2225-2236.
40. Lange P, Parner P, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with asthma. N Engl J Med 1998;339:1194-1200.
41. Menezes AM, Hallal PC, Perez-Padilla R, Jardim JR, Muiño A, Lopez MV, Valdivia G, Montes de Oca M, Talamo C, Pertuze J, et al.; Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO) Team. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J 2007;30: 1180-1185.
42. Tashkin DP. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest Dis 2005;63:93-100. (Pubitemid 41167514)
43. Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, McNaughton A, Robinson G, Beasley R. Effects of cannabis on pulmonary structure, function and symptoms. Thorax 2007;62:1058-1063. (Pubitemid 350206197)
44. Torres-Duque C, Maldonado D, Pérez-Padilla R, Ezzati M, Viegi G; Forum of International Respiratory Studies (FIRS) Task Force on Health Effects of Biomass Exposure. Biomass fuels and respiratory diseases: a review of the evidence. Proc Am Thorac Soc 2008;5:577-590.
45. Anonymous. COPD-more than just tobacco smoke. Lancet 2009;374: 663.
46. Eisner MD, Anthonisen N, Coultas D, Kuenzli N, Perez-Padilla R, Postma D, Romieu I, Silverman EK, Balmes JR; Committee on Nonsmoking COPD, Environmental and Occupational Health Assembly. An official American Thoracic Society public policy statement: novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693-718.
47. US Department of Health and Human Services. The health consequences of smoking: a report of the surgeon general. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health; 2004.
48. Lundbäck B, Lindberg A, Lindstrom M, Rönmark E, Jonsson AC, Jonsson E, Larsson LG, Andersson S, Sandström T, Larsson K, et al. Obstructive lung disease in Northern Sweden studies: not 15 but 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003;97:115-122. (Pubitemid 36284990)
49. Lindberg A, Bjerg-Backlund A, Ronmark E, Larsson LG, Lundback B. Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking: report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2006;100:264-272. (Pubitemid 43078978)
50. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the first National Health and Nutrition Examination Survey follow up study. Thorax 2003;58: 388-393. (Pubitemid 36560940)
51. Chilvers ER, Lomas DA. Diagnosing COPD in non-smokers: splitting not lumping. Thorax 2010;65:465-466.
52. Brandt AM. FDA regulation of tobacco-pitfalls and possibilities. N Engl J Med 2008;359:445-448.
53. Warren CP. The nature and causes of chronic obstructive pulmonary disease: a historical perspective. The Christie Lecture 2007, Chicago, USA. Can Respir J 2009;16:13-20.
54. Rennard SI, Vestbo J. The many ''small COPDs'': COPD should be an orphan disease. Chest 2008;134:623-627.
55. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, Macnee W, et al. COPD Phenotypes: the future of COPD. Am J Respir Crit Care Med 2010;582:598-604.
56. Grydeland TB, Dirksen A, Coxson HO, Pillai SG, Sharma S, Eide GE, Gulsvik A, Bakke PS. Quantitative computed tomography: emphysema and airway wall thickness by sex, age and smoking. Eur Respir J 2009;34:858-865.
57. Hyatt RE, Cowl CT, Bjoraker JA, Scanlon PD. Conditions associated with an abnormal nonspecific pattern of pulmonary function tests. Chest 2009;135:419-424.
58. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004;350:1005-1012. (Pubitemid 38269277)
59. Cote CG, Pinto-Plata VM, Marin JM, Nekach H, Dordelly LJ, Celli BR. The modified BODE index: validation with mortality in COPD. Eur Respir J 2008;32:1269-1274.
60. Soler-Cataluna JJ, Martinez-Garcia MA, Sanchez LS, Tordera MP, Sanchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med 2009; 103:692-699.
61. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Anto JM, Agusti AG, Gomez FP, Rodriguez-Roisin R, Moons KG, Kessels AG, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009;374:704-711.
62. Briggs A, Spencer M, Wang H, Mannino D, Sin DD. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med 2008;168:71-79.
63. Azarisman MS, Fauzi MA, Faizal MP, Azami Z, Roslina AM, Roslan H. The SAFE (SGRQ score, air-flow limitation and exercise tolerance) index: a new composite score for the stratification of severity in chronic obstructive pulmonary disease. Postgrad Med J 2007;83:492-497. (Pubitemid 47123323)
64. Jones RC, Donaldson GC, Chavannes NH, Kida K, Dickson-Spillmann M, Harding S, Wedzicha JA, Price D, Hyland ME. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease-the dose index. Am J Respir Crit Care Med 2009; 180:1189-1195.
65. Darwin C. On the origin of species by means of natural selection, or the preservation of favoured races in the struggle for life. London: John Murray; 1859.
66. Raherison C, Janson C, Jarvis D, Burney P, Cazzoletti L, de Marco R, Neukirch F, Leynaert B. Evolution of asthma severity in a cohort of young adults: is there any gender difference? PLoS ONE 2009;4: e7146.
67. Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, Nieminen MM, Kontula E, Laitinen LA. A 10 year asthma programme in Finland: major change for the better. Thorax 2006;61:663-670. (Pubitemid 44211772)
68. Kupczyk M, Haahtela T, Cruz AA, Kuna P. Reduction of asthma burden is possible through National Asthma Plans. Allergy 2010;65: 415-419.
69. Pietinalho A, Kinnula VL, Sovijärvi AR, Vilkman S, Säynäjäkangas O, Liippo K, Kontula E, Laitinen LA. Chronic bronchitis and chronic obstructive pulmonary disease: the Finnish Action Programme, interim report. Respir Med 2007;101:1419-1425. (Pubitemid 46844681)
70. Almagro P, Salvadó M, Garcia-Vidal C, Rodriguez-Carballeira M, Delgado M, Barreiro B, Heredia JL, Soriano JB. Recent improvement in long-term survival after a COPD hospitalisation. Thorax 2010;65:298-302.
71. Agusti A, Barnes PJ. What the journal would like to publish on chronic obstructive pulmonary disease.AmJRespirCritCareMed 2010;182:1-2.
72. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008;31:416-469.
73. Pinnock H, Thomas M, Tsiligianni I, Lisspers K, Østrem A, Stallberg B, Yusuf O, Ryan D, Buffels J, Cals JW, et al. The International Primary Care Respiratory Group (IPCRG) research needs statement 2010. Prim Care Respir J 2010;19:S1-S20.